An Open-Label, Multi-Centre, Randomized, Parallel-Group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy.

Trial Profile

An Open-Label, Multi-Centre, Randomized, Parallel-Group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Degarelix (Primary) ; Leuprorelin
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Acronyms ICHGCP
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 May 2017 Pooled results of trials (NCT00295750 and NCT00928434) presented at the 112th Annual Meeting of the American Urological Association
    • 22 Mar 2014 5-Year results from extension study published in the Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top